Tetraphase Pharmaceuticals (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that it has entered into an exclusive licensing agreement with Everest Medicines, a C-Bridge Capital-backed biopharmaceutical company based in China, to develop and commercialize eravacycline in mainland China, Taiwan,
CannaRoyalty announced its division CR Brands won six awards at the 2017 Hempcon Cup Awards for their line of cannabis products.
3D Signatures Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) (the “Company” or “3DS”) is pleased to announce that a preliminary third-party analysis of the trial data for Telo-HLTM, 3DS’ test in development for Hodgkin’s lymphoma (HL), shows that the Company’s TeloViewTM platform is able to distinguish, with a high degree of statistical significance,
Venzee Technologies Inc (TSXV:VENZ) (“Venzee” or the “Company”) is pleased to announce that the award-winning interior design firm and nationwide home decor e-retailer, Venue, has selected Venzee to automate the process of adding and updating products sold on venueathome.com.
By Melissa Shaw
Higher potash and phosphate prices contributed to a 12-percent rise in Mosaic’s net sales in Q4 2017, and have benefited other producers too.
By Jocelyn Aspa
eGain, Synchronoss Technologies, Park City Group, Meet Group and Avid Technology were last week’s top gainers.
This past week the NASDAQ Biotechnology Index increased by 4.15 percent reaching 3,501.80 points in the last week—nearly equal to it’s year-to-date (YTD) increase. YTD the NBI increased 4.3 percent as of 1:00 p.m. EST Friday.
The Investing News Network rounds some of the biggest news in the cannabis market for the past trading week
Oil prices have fallen 15 percent in the last three weeks, and analysts are now warning that prices will only continue to decline.
In case you missed it, here is this week’s big news roundup.
In case you missed it, here is this week’s cannabis big news roundup.
Immuron (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of many gut mediated diseases, is pleased to announce its half year sales results of its commercially available and over-the-counter gastrointestinal and digestive health supplement Travelan.
As quoted in the press release:
Immuron Marketing Manager
Hiku Brands Company Ltd. (“Hiku” or the “Company”) (CSE: HIKU), is pleased to announce that its wholly-owned subsidiary, Tokyo Smoke, with participation by BOBHQ, has been conditionally awarded one of four master retail licenses (the “License”) in Manitoba’s highly competitive Request for Proposal (“RFP”) process for the right to operate
Connect with our Featured Silver Stocks to receive the latest news and investor presentations.